Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes
| Field | Value | Language |
| dc.contributor.author | Tan, RH | |
| dc.contributor.author | Kril, JJ | |
| dc.contributor.author | Yang, Y | |
| dc.contributor.author | Tom, N | |
| dc.contributor.author | Hodges, JR | |
| dc.contributor.author | Villemagne, VL | |
| dc.contributor.author | Rowe, CC | |
| dc.contributor.author | Leyton, CE | |
| dc.contributor.author | Kwok, JBJ | |
| dc.contributor.author | Ittner, LM | |
| dc.contributor.author | Halliday, GM | |
| dc.date.accessioned | 2018-12-12 | |
| dc.date.available | 2018-12-12 | |
| dc.date.issued | 2017-05-29 | |
| dc.identifier.citation | Tan RH, Kril JJ, Yang Y, et al. Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes. Alzheimers Dement (Amst). 2017;9:10-20. Published 2017 May 29. doi:10.1016/j.dadm.2017.05.005 | en_AU |
| dc.identifier.uri | http://hdl.handle.net/2123/19653 | |
| dc.description.abstract | The diagnostic utility of in vivo amyloid β (Aβ) imaging to aid in the clinical distinction between frontotemporal dementia (FTD) and Alzheimer's disease remains unclear without data on the prevalence and severity of Aβ in pathologically confirmed FTD syndromes. | en_AU |
| dc.description.sponsorship | NHMRC RGMS ID P02927884 | en_AU |
| dc.language.iso | en_AU | en_AU |
| dc.publisher | Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | en_AU |
| dc.relation | NHMRC RGMS ID P02927884 | en_AU |
| dc.rights | CC BY-NC-ND license | en_AU |
| dc.subject | Neuropathology | en_AU |
| dc.title | Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes | en_AU |
| dc.type | Article | en_AU |
| dc.identifier.doi | http://dx.doi.org/10.1016/j.dadm.2017.05.005 | |
| dc.type.pubtype | Publisher's version | en_AU |
Associated file/s
Associated collections